As is to be expected from our results with γ-secretase inhibitors, how would AD-linked PS1 mutations and γ-secretase modulaters (GSMs) targeting the γ-secretase active site modulate the cleavage of full-length APLP1 and what would be the consequences for AD development and such treatment approaches? Here, APLP1 is linked to Alzheimer disease.